{"groups":[{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG000","title":"Vincristine Sulfate Liposome Injection: 1.8 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG001","title":"Vincristine Sulfate Liposome Injection: 1.95 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG002","title":"Vincristine Sulfate Liposome Injection: 1.98 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG003","title":"Vincristine Sulfate Liposome Injection: 2.04 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG004","title":"Vincristine Sulfate Liposome Injection: 2.10 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG005","title":"Vincristine Sulfate Liposome Injection: 2.14 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG006","title":"Vincristine Sulfate Liposome Injection: 2.19 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG007","title":"Vincristine Sulfate Liposome Injection: 2.22 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"FG008","title":"Vincristine Sulfate Liposome Injection: 2.24 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"1 subject removed from study before any treatment due to temporary unavailability of study drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}